• Dovitinib: Chamber-Specific Assay Design

  2026-09-10

  Dovitinib (TKI-258) combines broad RTK inhibition with a useful framework for dissecting pathway-dependent apoptosis in cancer models. This article adds a distinct assay-design perspective by connecting oncology pharmacology with chamber-specific human stem cell-derived cardiomyocytes while clearly separating established evidence from testable applications.

• Laminin (925-933) Workflow for Adhesion Assays

  2026-09-10

  Laminin (925-933) is a defined Laminin B1 chain peptide for separating peptide-mediated cell attachment and chemotaxis from the broader complexity of full-length laminin. This guide covers stock preparation, adhesion and migration assay setup, controls, and limitations; it is intended for research workflows only, not diagnostic, therapeutic, or clinical use.

• JNJ-10198409: A Systems-Level PDGF Assay Strategy

  2026-09-09

  JNJ-10198409 is a platelet-derived growth factor receptor inhibitor suited to mechanistic studies of ATP-competitive kinase blockade, proliferation, and angiogenesis. This article develops an assay strategy that connects PDGF-BB target engagement with the stage-dependent signaling logic revealed by recent host–pathogen research.

• Ferroptosis Signature Identifies Atorvastatin in HCC

  2026-09-09

  A 2025 study integrated ferroptosis-related transcriptomics, survival modeling, Connectivity Map screening, and laboratory validation to develop a four-gene prognostic signature for hepatocellular carcinoma. The analysis nominated Atorvastatin as a potential ferroptosis-inducing treatment candidate, although the evidence remains preclinical and requires independent validation.

• Miltefosine Activates ERK to Restore Neutrophils

  2026-09-08

  A 2025 study identifies Miltefosine as a potential leukopenia intervention that promotes neutrophil differentiation through Ras/MEK/ERK signaling. Using leukemia-cell models, an irradiation-induced mouse model, transcriptomics, network pharmacology, molecular docking, and pathway inhibition, the authors connect Miltefosine exposure with improved myelopoiesis and neutrophil function.

• Radicicol: From Hsp90 Biology to Translational Design

  2026-09-08

  Radicicol is more than an Hsp90 inhibitor: it is a mechanistic probe for testing how chaperone dependence, kinase signaling, apoptosis, adipogenesis, and inflammation intersect. This thought-leadership article connects Radicicol pharmacology with new evidence on HSP90-dependent antigen cross-presentation and translates those insights into assay and study-design guidance.

• Trichostatin A (TSA): Reliable Cell Assays

  2026-09-07

  A scenario-driven guide to using Trichostatin A (TSA), SKU A8183, in viability, proliferation, and cytotoxicity workflows. It connects HDAC biology with solvent control, dose-response design, endpoint interpretation, and practical product selection.

• Protease Inhibitor Cocktail for Phospho-Protein Workflows

  2026-09-07

  Protect labile proteins during cell and tissue lysis with an EDTA-free, broad-spectrum formulation suited to Western blotting, co-immunoprecipitation, kinase assays, and signaling studies. This workflow connects protease inhibition in cell lysates with the IκBα–NF-κB experiments reported in p53-mutant lymphoma research, while addressing DMSO, phosphorylation, and sample-quality pitfalls.

• BHPF–GPER Binding and Neuroblastoma Apoptosis

  2026-09-05

  The 2024 reference study identifies fluorene-9-bisphenol (BHPF) as a direct functional inhibitor of GPER, rather than simply an unconventional estrogen-active contaminant. By combining molecular dynamics, receptor perturbation, mutagenesis, calcium signaling, cytotoxicity, and gene-expression assays, the authors connect two receptor residues with BHPF recognition and impaired GPER signaling.

• Bsa I (RNase-free): DNA Cleavage Guide

  2026-09-04

  Bsa I (RNase-free) provides sequence-directed DNA cleavage for molecular biology research, gene cloning, and recombinant DNA workflows in which RNA contamination should be minimized. It is intended for controlled scientific research only and should not be used for diagnostic, clinical, or medical applications.

• Leucomycin: Composition-Aware Assay Design

  2026-09-04

  Leucomycin and kitasamycin are best interpreted as a bioactive macrolide complex, not simply as a single analyte. This guide connects component composition, ribosomal inhibition, resistance, formulation, and assay design to improve antibacterial research decisions.

• Vernakalant Hydrochloride: From Channel Block to PK/PD

  2026-09-03

  Vernakalant Hydrochloride (RSD1235) offers a powerful model for connecting atrial ion-channel pharmacology with clinically interpretable exposure–response data. This guide translates its PK/PD evidence into practical assay-design, concentration-selection, and translational decision frameworks.

• CD28–ARS2–PKM2 Metabolic Flexibility in CD8+ T Cells

  2026-09-03

  The reference study identifies a CD28–ARS2 signaling axis that reshapes PKM alternative splicing and promotes PKM2-dependent metabolic flexibility in activated CD8+ T cells. Its findings connect costimulatory signaling with glucose utilization, interferon-γ production, and antitumor activity through a mechanism that is distinct from canonical CD28–PI3K signaling.

• Caspase-6 Inhibition in Translational Cell Death Research

  2026-09-02

  A mechanistic and strategic guide to using Z-VEID-FMK as a causal probe in apoptosis research, with a focus on separating caspase-6 activity from caspase-1-driven pyroptosis in lung cancer models.

• Dual Viability Metrics in Cancer Drug Response Studies

  2026-09-02

  Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. Its central insight is that drug-induced growth inhibition and cell death often occur together but differ in magnitude and timing, requiring assays and interpretations that separate these biological outcomes.

8526 records 1/569 page Next 12345 下5页 Last page